Capricor Therapeutics, Inc. Share Price & Technical Analysis
CAPR · $29.20 (+1.14%)
Healthcare / Biotechnology
$29.20
+1.14%
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatm…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-14% return in May, 1% avg return in past 3 year May month.
14% return in 2026, 227% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -25% | 28% | 14% | 10% | -14% | – | – | – | – | – | – | – | 14% |
| 25 | 7% | 7% | -38% | 32% | -21% | -1% | -15% | -20% | 14% | -10% | -17% | 445% | 383% |
| 24 | -18% | 5% | 55% | -22% | 8% | -16% | -16% | 12% | 230% | 32% | -5% | -28% | 236% |
| 23 | 8% | 10% | -11% | -7% | 15% | 7% | -8% | 48% | -48% | -20% | 7% | 63% | 64% |
| 22 | 24% | 14% | -19% | -6% | 16% | -5% | 31% | 26% | 3% | -8% | -20% | -15% | 42% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.80B
P/E ratio
—
52W high
$40.37
52W low
$4.30
Volume
3,86,316
Beta
0.48
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Capricor Therapeutics, Inc. share price today?
- Capricor Therapeutics, Inc. (CAPR) last traded around $29.20 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CAPR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CAPR. Download the app for real-time alerts.
- How can I analyze Capricor Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.